Recent Updates
Recently added Catalysts
ATHE Positive Sentiment Score: 85/100

Results of Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") advises that all resolutions considered at the

Wednesday, November 29, 2023 1 min read
Key Takeaway: Alterity Therapeutics held its Annual General Meeting on November 29, 2023, where all resolutions were passed by poll. The results showed strong support from shareholders, with significant percentages voting in favor of the non-binding remuneration report, the re-election of directors, and the ratification of prior share issues. Additionally, the approval of a 10% placement facility was granted to enhance their financing capabilities.

Market Sentiment Analysis

POSITIVE FACTORS

  • All resolutions were successfully carried by poll during the AGM.
  • High percentages of votes in favor for key directors and resolutions indicate strong shareholder support.
  • The approval of the 10% placement facility supports future financing options.

Full Press Release Details

Results of Annual General
MELBOURNE, AUSTRALIA AND SAN
FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company")
advises that all resolutions considered at the Annual General Meeting held today were carried by poll.
In accordance with ASX Listing
rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution
Alterity Therapeutics Limited
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com
The following information is provided in accordance with
section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) Resolution Result
Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain* Carried / Not Carried
1 Non-binding resolution to adopt Remuneration Report Ordinary 80,616,129 76.83% 21,954,866 20.92% 2,360,040 2.25% 14,602,600 89,426,169 80.29% 21,954,866 19.71% 14,602,600 Carried
2 Re-Election of Director Mr. Peter Marks Ordinary 106,311,290 85.25% 16,351,485 13.11% 2,043,660 1.64% 12,043,800 118,077,176 87.84% 16,351,485 12.16% 12,043,800 Carried
3 Re-Election of Director Mr. Lawrence Gozlan Ordinary 106,475,730 85.62% 15,842,045 12.74% 2,043,660 1.64% 12,022,800 118,241,616 88.18% 15,842,045 11.82% 12,022,800 Carried
4 Ratification of prior issue of shares (Placement March 2023) Ordinary 115,193,651 85.81% 17,027,399 12.68% 2,033,660 1.51% 3,043,925 126,949,537 88.17% 17,027,399 11.83% 3,043,925 Carried
5 Approval of 10% Placement Facility Special 111,296,889 83.43% 19,861,399 14.89% 2,243,660 1.68% 3,896,687 123,262,775 86.12% 19,861,399 13.88% 3,896,687 Carried

Frequently Asked Questions

What was the outcome of the Annual General Meeting?

All resolutions at the Annual General Meeting were approved by poll.

How did shareholders vote on the Remuneration Report?

The Remuneration Report was approved with 80.29% votes in favor.

Who were re-elected as directors of Alterity?

Mr. Peter Marks and Mr. Lawrence Gozlan were both re-elected as directors.

What was ratified in regard to prior share issuance?

The ratification of the prior issue of shares from March 2023 was approved.

Was the 10% Placement Facility approved?

Yes, the 10% Placement Facility received 86.12% approval from shareholders.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics AGM results shareholder support Australia
Last updated: Nov 29, 2023